MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
GUANGZHOU, China, May 6, 2026 /PRNewswire/ -- MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II clinical trial of QA102 in patients with intermediate dry age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the...
Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026)
HONG KONG, May 6, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the 33rd European Congress on Obesity (ECO 2026), taking place May 12-15, 2026 in Istanbul, Türkiye. The presentations include a poster on the Phase I data of ASC47, an adipose-targeting...
ESOC 2026: Rising stroke rates highlight widening ethnic and socioeconomic inequalities across populations, major study finds
MAASTRICHT, Netherlands, May 6, 2026 /PRNewswire/ -- A new study presented today at the European Stroke Organisation Conference (ESOC) 2026 shows that after decades of decline, stroke incidence is rising again, driven by higher rates in some ethnic minority populations and concentrated among socioeconomically disadvantaged groups. These findings reflect broader patterns seen in diverse urban populations internationally, pointing to widening...
Norgine welcomes TGA registration in Australia of PEDMARQSI® (sodium thiosulfate anhydrous) for the prevention of cisplatin-induced hearing loss in children1
PEDMARQSI® is now TGA registered in Australia for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localised, non-metastatic, solid tumours TGA registration provides an approved treatment option in an area of significant unmet medical need for children receiving cisplatin chemotherapy ...
CAI Launches Next Chapter with Investment from JLL Partners
INDIANAPOLIS, May 5, 2026 /PRNewswire/ -- CAI, a professional services firm dedicated to accelerating operational readiness and excellence in life sciences and mission-critical environments, today announced that it has entered into an agreement with JLL Partners, a New York-based middle-market private equity firm focused on investing in the healthcare, industrials, and business services sectors, to...
AI Model Analyses Body Composition to Predict Health Risks
OAK BROOK, Ill., May 5, 2026 /PRNewswire/ -- Researchers used AI to analyze whole-body MRI scans from more than 66,000 participants to create the most detailed reference map to date of how fat and muscle are distributed in the human body across age, sex and height. The study was published today in...
Hidden Muscle Fat Poses Danger to Heart, Metabolism
OAK BROOK, Ill., May 5, 2026 /PRNewswire/ -- Using a deep learning model to analyze the composition of large muscles on MRI, German researchers found that the proportions of intermuscular fat and lean muscle mass were associated with high blood pressure and unhealthy lipid and blood sugar levels. Results of the study...
BostonGene Receives Frost & Sullivan’s 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms
Recognition highlights BostonGene's leadership in improving drug development decisions,reducing risk and accelerating patient impact SAN ANTONIO, May 5, 2026 /PRNewswire/ -- Frost & Sullivan is pleased to announce that BostonGene has been recognized as the 2026 Global Company of the Year in AI-Driven Multimodal Oncology Platforms. This recognition highlights BostonGene's leadership in improving drug development decisions through its AI foundation model...
BGM0504 Achieves 19.3% Robust Weight Reduction, 16.5 cm Waist Circumference Decrease, Significant SBP/DBP Improvements of 22.9/12.9 mmHg, and 70.7 μmol/L Uric Acid Reduction; Phase III Trial Meets Primary Endpoint...
SUZHOU, China, May 5, 2026 /PRNewswire/ -- BrightGene Bio-Medical Technology Co., Ltd. (hereinafter referred to as " BrightGene Bio-Medical" or "the Company") announced that its proprietary GLP-1 (glucagon-like peptide-1)/GIP (glucose-dependent insulinotropic polypeptide) dual receptor agonist, BGM0504 injection, has achieved positive topline results from a Phase III clinical trial (Study No.: BGM0504-III-WL) evaluating its efficacy and safety in participants with overweight...
3Shape appoints new Chief Financial Officer
COPENHAGEN, Denmark, May 5, 2026 /PRNewswire/ -- 3Shape today announced the appointment of Stefan Kratzer as Chief Financial Officer effective 5 May. He will join the Senior Leadership Team and report directly to CEO Jacob Paulsen. The appointment ensures strong leadership continuity, with an experienced successor stepping into the role. "As we enter the next phase of our journey, it...
